Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal

Dr. Betrand Tombal discusses the ongoing PEACE III trial evaluating enzalutamide alone versus enzalutamide plus radium-223 post the ERA-223 data.  The interim safety analysis was presented at ASCO and the data demonstrated that there was an increase fracture rate with the addition of radium-223 to enzalutamide prior to mandating use of bone protecting agents.  Pathological and non-pathological fractures are a well recognized complication in advanced prostate cancer but the early results of the PEACE III trial demonstrate that the risk can be controlled in both arms when patients receive bone protecting agents, including denosumab and zoledronic acid.   

Biographies:

Bertrand F. Tombal, MD, PhD, Professor and Chair, Université Catholique de Louvain, Brussels, Belgium

Thomas Keane, MBBCh, FRCSI, FACS , Professor and Chairman of the Department of Urology at the Medical University of South Carolina, Charleston, South Carolina. He holds a U.S. patent for BNCT in prostate cancer and sphingolipid derivatives and their use.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe